New data suggest that plasma soluble urokinase receptor (suPAR) might be a predictive biomarker and potential therapeutic target for acute kidney injury (AKI). However, many questions remain regarding the potential of suPAR to inform clinical decision making, identify patients for enrolment in clinical trials and add to the understanding of AKI pathogenesis.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Acute kidney injury in the critically ill: an updated review on pathophysiology and management
Intensive Care Medicine Open Access 02 July 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hayek, S. S. et al. Soluble urokinase receptor and acute kidney injury. N. Engl. J. Med. 382, 416–426 (2020).
American Society of Nephrology Renal Research Report. J. Am. Soc. Nephrol. 16, 1886–1903 (2005).
Griffin, B. R., Gist, K. M. & Faubel, S. Current status of novel biomarkers for the diagnosis of acute kidney injury: a historical perspective. J. Intensive Care Med. 35, 415–424 (2020).
Zarbock, A. et al. Effect of early versus delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN Randomized Clinical Trial. JAMA 315, 2190–2199 (2016).
Endre, Z. H. et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int. 77, 1020–1030 (2010).
Meersch, M. et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med. 43, 1551–1561 (2017).
Goldstein, S. L. et al. A prospective multi-center quality improvement initiative (NINJA) indicates a reduction in nephrotoxic acute kidney injury in hospitalized children. Kidney Int. 97, 580–588 (2020).
Koyner, J. L., Zarbock, A., Basu, R. K. & Ronco, C. The impact of biomarkers of acute kidney injury on individual patient care. Nephrol. Dial. Transplant. https://doi.org/10.1093/ndt/gfz188 (2019).
Faubel, S. et al. Ongoing clinical trials in AKI. Clin. J. Am. Soc. Nephrol. 7, 861–873 (2012).
Skrypnyk, N. I. et al. IL-6-mediated hepatocyte production is the primary source of plasma and urine neutrophil gelatinase-associated lipocalin during acute kidney injury. Kidney Int. https://doi.org/10.1016/j.kint.2019.11.013 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Faubel, S. SuPAR: a potential predictive biomarker for acute kidney injury. Nat Rev Nephrol 16, 375–376 (2020). https://doi.org/10.1038/s41581-020-0276-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-020-0276-7
